Patents by Inventor Konan Peck
Konan Peck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10533179Abstract: Aptamers that bind to and inhibit CTLA-4 and uses thereof in enhancing immune activities, and treating cancer and HIV infection are provided.Type: GrantFiled: July 31, 2015Date of Patent: January 14, 2020Assignees: Academia Sinica, National Taiwan University, Taipei Medical UniversityInventors: Konan Peck, Pan-Chyr Yang, Yi-Chung Chang, Bo-Tsang Huang, Shauh-Der Yeh
-
Patent number: 9891227Abstract: Methods of assaying a biological target are disclosed. The method comprises: (a) providing a sample containing the biological target; (b) providing biotin-labeled first aptamers conjugated to a gold nanoparticle (GNP), and second aptamers conjugated to a magnetic bead, wherein the first and the second aptamers exhibit specific binding affinities to the target; (c) incubating the sample with the first and the second aptamers to obtain target-bound aptamers; (d) separating the target-bound aptamers from unbound aptamers; (e) eluting the first aptamers from the GNP; (f) incubating the eluted biotin-labeled first aptamers with streptavidin-magnetic beads and reporter gold nanoparticles (GNPs) to obtain a complex comprising: the bead, the first aptamers, attached to the bead; and the reporter GNPs captured by the bead through the first aptamers; (g) eluting the reporter GNPs captured; and (h) detecting the target by measuring and analyzing a light-scattering signal of the eluted reporter GNPs.Type: GrantFiled: April 30, 2015Date of Patent: February 13, 2018Assignee: ACADEMIA SINICAInventors: Konan Peck, Pan-Chyr Yang, Yi-Chung Chang
-
Patent number: 9856480Abstract: The invention provides DNAzymes which are capable to silence the expression of EGFR at allele-specific level. These allele-specific DNAzymes against EGFR T790M mutation will knockdown the expression of EGFR T790M mRNA while keeping EGFR wild-type mRNA intact. Hence, these allele-specific DNAzymes against EGFR T790M mutation may overcome T790M-derived TKI resistance accompanied with lower unwanted side effects on normal cells in lung cancer patients.Type: GrantFiled: January 14, 2014Date of Patent: January 2, 2018Assignees: National Taiwan University, ACADEMIA SINICAInventors: Pan-Chyr Yang, Wei-Yun Lai, Konan Peck, Cheng-Ju Chang, Chi-Yuan Chen, Shuenn-Chen Yang
-
Publication number: 20170211067Abstract: Aptamers that bind to and inhibit CTLA-4 and uses thereof in enhancing immune activities, and treating cancer and HIV infection are provided.Type: ApplicationFiled: July 31, 2015Publication date: July 27, 2017Applicants: Academia Sinica, National Taiwan University, Taipei Medical UniversityInventors: Konan Peck, Pan-Chyr Yang, Yi-Chung Chang, Bo-Tsang Huang, Shauh-Der Yeh
-
Publication number: 20160145625Abstract: The invention provides DNAzymes which are capable to silence the expression of EGFR at allele-specific level. These allele-specific DNAzymes against EGFR T790M mutation will knockdown the expression of EGFR T790M mRNA while keeping EGFR wild-type mRNA intact. Hence, these allele-specific DNAzymes against EGFR T790M mutation may overcome T790M-derived TKI resistance accompanied with lower unwanted side effects on normal cells in lung cancer patients.Type: ApplicationFiled: January 14, 2014Publication date: May 26, 2016Applicant: Academia SinicaInventors: Pan-Chyr Yang, Wei-Yun Lai, Konan Peck
-
Publication number: 20150316545Abstract: Methods of assaying a biological target are disclosed. The method comprises: (a) providing a sample containing the biological target; (b) providing biotin-labeled first aptamers conjugated to a gold nanoparticle (GNP), and second aptamers conjugated to a magnetic bead, wherein the first and the second aptamers exhibit specific binding affinities to the target; (c) incubating the sample with the first and the second aptamers to obtain target-bound aptamers; (d) separating the target-bound aptamers from unbound aptamers; (e) eluting the first aptamers from the GNP; (f) incubating the eluted biotin-labeled first aptamers with streptavidin-magnetic beads and reporter gold nanoparticles (GNPs) to obtain a complex comprising: the bead, the first aptamers, attached to the bead; and the reporter GNPs captured by the bead through the first aptamers; (g) eluting the reporter GNPs captured; and (h) detecting the target by measuring and analyzing a light-scattering signal of the eluted reporter GNPs.Type: ApplicationFiled: April 30, 2015Publication date: November 5, 2015Inventors: Konan PECK, Pan-Chyr Yang, Yi-Chung Chang
-
Publication number: 20090220985Abstract: The present invention discloses a method for rapid assessment of lung cancer therapy efficacy in a few days instead of weeks by conventional imaging methods. This method can also be used to detect relapse of the cancer and to improve the current TNM cancer staging method for more accurate prognosis. The rapid assessment of therapy efficacy is based on detecting circulating cancer cells in body fluid with high positive detection rate. The high positive detection rate is achieved by using qPCR amplification of multiple marker genes identified by in silico search of DNA sequence database. This invention also discloses a scoring method to calculate the cancer cell load based on qPCR results to correlate the amount of circulating cancer cells in lung cancer patients and predict the treatment outcomes.Type: ApplicationFiled: March 24, 2009Publication date: September 3, 2009Applicant: National Health Research InstitutesInventors: Konan Peck, Yuh-Pyng Sher, Jin-Yuan Shih, Pan-Chyr Yang, Cheng-Wen Wu
-
Patent number: 7507534Abstract: The present invention discloses a method for rapid assessment of lung cancer therapy efficacy in a few days instead of weeks by conventional imaging methods. This method can also be used to detect relapse of the cancer and to improve the current TNM cancer staging method for more accurate prognosis. The rapid assessment of therapy efficacy is based on detecting circulating cancer cells in body fluid with high positive detection rate. The high positive detection rate is achieved by using qPCR amplification of multiple marker genes identified by in silico search of DNA sequence database. This invention also discloses a scoring method to calculate the cancer cell load based on qPCR results to correlate the amount of circulating cancer cells in lung cancer patients and predict the treatment outcomes.Type: GrantFiled: December 31, 2005Date of Patent: March 24, 2009Assignee: National Health Research InstitutesInventors: Konan Peck, Yuh-Pyng Sher, Jin-Yuan Shih, Pan-Chyr Yang, Cheng-Wen Wu
-
Patent number: 7354709Abstract: This invention is based on the discovery of an association of Collapsin Response Mediator Protein-1 (CRMP-1) with tumor metastasis. The level of CRMP-1 protein or mRNA can be used as an indicator of cellular invasiveness and of a test compound's ability to alter cellular invasiveness. The level of CRMP-1 protein can also be altered, e.g., to reduce invasiveness.Type: GrantFiled: June 25, 2002Date of Patent: April 8, 2008Assignees: National Taiwan University, Academia Sinica, National Health Research InstitutesInventors: Pan-Chyr Yang, Jin-Yuan Shih, Jeremy J. W. Chen, Konan Peck, Cheng-Wen Wu, Tse-Ming Hong, Shuenn-Chen Yang
-
Publication number: 20070048750Abstract: The present invention discloses a method for rapid assessment of lung cancer therapy efficacy in a few days instead of weeks by conventional imaging methods. This method can also be used to detect relapse of the cancer and to improve the current TNM cancer staging method for more accurate prognosis. The rapid assessment of therapy efficacy is based on detecting circulating cancer cells in body fluid with high positive detection rate. The high positive detection rate is achieved by using PCR amplification of multiple marker genes identified by in silico search of DNA sequence database. This invention also discloses a scoring method to calculate the cancer cell load based on PCR results to correlate the amount of circulating cancer cells in lung cancer patients with their treatment outcomes.Type: ApplicationFiled: December 31, 2005Publication date: March 1, 2007Applicant: NATIONAL HEALTH RESEARCH INSTITUTEInventors: Konan Peck, Yuh-Pyng Sher, Jin-Yuan Shih, Pan-Chyr Yang, Cheng-Wen Wu
-
Patent number: 6867050Abstract: Apparatuses and methods are described for parallel oligonucleotide synthesis of hundreds of different sequences and lengths at a time. Standard phosphoramidite chemistry is employed. The syntheses take place in a reaction plate compatible with the industrial standard microplate format to allow the use of readily available automated instruments for subsequent processing. Key parameters in reducing synthesis volume in small reaction wells are discussed. This invention provides solutions to the difficulties of low volume, high number synthetic reactions.Type: GrantFiled: August 6, 2001Date of Patent: March 15, 2005Assignee: Academia SinicaInventors: Konan Peck, Ji-Yen Cheng
-
Publication number: 20030207270Abstract: The present invention provides the tools and methodologies necessary to guide the standardization of herbal compositions, to determine which specific components of an herbal composition are responsible for any particular biological activity, to predict the biological activities of a particular herbal composition, to determine the relatedness of herbal compositions, and for the development of improved herbal therapeutics. This invention provides the tools and methodologies for creating, maintaining, improving and utilizing Herbal BioResponse Arrays (HBR Arrays), wherein the HBR Arrays constitute data sets associated with particular herbal compositions.Type: ApplicationFiled: August 2, 2002Publication date: November 6, 2003Inventors: Patrick C. Kung, Konan Peck, Yun-Shien Lee, Yuh-Pyng Sher, Yung-Chi Cheng
-
Publication number: 20030077624Abstract: This invention is based on the discovery of an association of Collapsin Response Mediator Protein-1 (CRMP-1) with tumor metastasis. The level of CRMP-1 protein or mRNA can be used as an indicator of cellular invasiveness and of a test compound's ability to alter cellular invasiveness. The level of CRMP-1 protein can also be altered, e.g., to reduce invasiveness.Type: ApplicationFiled: June 25, 2002Publication date: April 24, 2003Inventors: Pan-Chyr Yang, Jin-Yuan Shih, Jeremy J. W. Chen, Konan Peck, Cheng-Wen Wu, Tse-Ming Hong, Shuenn-Chen Yang
-
Publication number: 20030054387Abstract: Many genes are identified as being metastasis associated. Identifying and profiling of these genes expression can be used to evaluate a sample, to diagnose tumor invasive potential or metastatic development in a sample, or screen for a test compound useful in the prevention or treatment of tumor metastasis.Type: ApplicationFiled: June 25, 2002Publication date: March 20, 2003Inventors: Jeremy J.W. Chen, Pan-Chyr Yang, Konan Peck, Tse-Ming Hong, Shuenn-Chen Yang, Cheng-Wen Wu
-
Publication number: 20020176811Abstract: Apparatuses and methods are described for parallel oligonucleotide synthesis of hundreds of different sequences and lengths at a time. Standard phosphoramidite chemistry is employed. The syntheses take place in a reaction plate compatible with the industrial standard microplate format to allow the use of readily available automated instruments for subsequent processing. Key parameters in reducing synthesis volume in small reaction wells are discussed. This invention provides solutions to the difficulties of low volume, high number synthetic reactions.Type: ApplicationFiled: August 6, 2001Publication date: November 28, 2002Inventors: Konan Peck, Ji-Yen Cheng
-
Patent number: 6428667Abstract: Novel fluorescent labeling techniques and fluorescent labels are provided, employing high affinity non-covalently binding and intercalating fluorescent dyes and dsDNA. The dyes find application to provide highly sensitive labeling of nucleic acids in electrophoretic gels and as pre-prepared labels for binding to a wide variety of specific binding pair members. The DNA-dye fluorescer complex can be used for labels in diagnostic assays, detection of specific nucleic acid sequences, and the like.Type: GrantFiled: October 10, 2000Date of Patent: August 6, 2002Assignee: The Regents of the University of California, BerkeleyInventors: Alexander N. Glazer, Richard A. Mathies, Konan Peck
-
Patent number: 6280933Abstract: Novel fluorescent labeling techniques and fluorescent labels are provided, employing high affinity non-covalently binding and intercalating fluorescent dyes and dsDNA. The dyes find application to provide highly sensitive labeling of nucleic acids in electrophoretic gels and as pre-prepared labels for binding to a wide variety of specific binding pair members. The DNA-dye fluorescer complex can be used for labels in diagnostic assays, detection of specific nucleic acid sequences, and the like.Type: GrantFiled: November 7, 1997Date of Patent: August 28, 2001Assignee: The Regents of the University of CaliforniaInventors: Alexander N. Glazer, Richard A. Mathies, Konan Peck
-
Patent number: 6218114Abstract: The invention relates to a method of detecting a differentially expressed gene in a first sample of nucleic acids representing a first population of RNA transcripts and a second sample of nucleic acids representing a second population of RNA transcripts. The nucleic acids in the samples are labled with a member of specific binding pair, and the labeled nucleic acids in each sample are then hybridized to an excess of copies of a gene-specific sequence. The hybridized nucleic acids in each sample are further labeled by binding a second member of the specific binding pair to the first member, in which the second member has an activity to convert a chromogenic substrate into a chromogen. As a result of contacting the second member with the chromogenic substrate, the chromogenic substrate is converted into the chromogen. A difference in the amounts of chromogen produced from assaying the two samples indicate that the gene-specific sequence is differentially expressed in the samples.Type: GrantFiled: March 27, 1998Date of Patent: April 17, 2001Assignee: Academia SinicaInventors: Konan Peck, Jeremy J. W. Chen, Pan-Chyr Yang, Reen Wu, Fu Chang, Yi-Wen Chu, Cheng-Wen Wu
-
Patent number: 5789173Abstract: The present invention discloses a method for rapid antimicrobial susceptibility testing to screen antibiotics in a few hours instead of days by conventional methods. This method can also be used to identify susceptible antibiotics to treat mycobacterial infection in a few days instead of the usual six to eight weeks. Fast screening of antibiotics is achieved by a short period of specimen incubation in different antibiotics embedded media to create differential bacterial counts. The differences of bacterial counts among antibiotics embedded media are subsequently amplified by DNA amplification methods for detection. Following DNA amplification, rapid quantitation and minimum inhibition concentration (MIC) determinations for a panel of antibiotics are achieved in less than one minute by fluorescence quantitation methods.Type: GrantFiled: August 2, 1996Date of Patent: August 4, 1998Assignee: Academia SinicaInventors: Konan Peck, Pan-Chyr Yang, Shu-Li Wung
-
Patent number: 5763162Abstract: Novel fluorescent labeling techniques and fluorescent labels are provided, employing high affinity non-covalently binding and intercalating fluorescent dyes and dsDNA. The dyes find application to provide highly sensitive labeling of nucleic acids in electrophoretic gels and as pre-prepared labels for binding to a wide variety of specific binding pair members. The DNA-dye fluorescer complex can be used for labels in diagnostic assays, detection of specific nucleic acid sequences, and the like.Type: GrantFiled: December 2, 1993Date of Patent: June 9, 1998Assignee: The Regents of University of CaliforniaInventors: Alexander N. Glazer, Richard A. Mathies, Konan Peck